The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. have formed a strategic alliance.

This alliance will use Moderna's mRNA platform to expedite vaccine research against viral disease outbreaks that threaten global health.

The collaboration's study could broaden the infectious disease targets for mRNA vaccine technology.

This will also strengthen pandemic preparedness and public health activities in line with the 100-Day Mission.

The 100-day mission aims to limit vaccine development to 100 days.

mRNA technology has been identified as an essential driver of the 100 Days Mission due to its versatility as a rapid-response platform.

mRNA technology can be leveraged to design and swiftly prepare novel vaccines for clinical testing and subsequent scale-up.

This technology can potentially help in scaling up new vaccines within days of recognizing a new viral threat.